Literature DB >> 25362122

Negative clinical trials in sarcoidosis: failed therapies or flawed study design?

David R Moller1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25362122     DOI: 10.1183/09031936.00156314

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  5 in total

Review 1.  Treatment of Sarcoidosis.

Authors:  Robert P Baughman; Elyse E Lower
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

2.  Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

Authors:  William Damsky; Alice Wang; Daniel J Kim; Bryan D Young; Katelyn Singh; Michael J Murphy; Joseph Daccache; Abigale Clark; Ruveyda Ayasun; Changwan Ryu; Meaghan K McGeary; Ian D Odell; Ramesh Fazzone-Chettiar; Darko Pucar; Robert Homer; Mridu Gulati; Edward J Miller; Marcus Bosenberg; Richard A Flavell; Brett King
Journal:  Nat Commun       Date:  2022-06-06       Impact factor: 17.694

3.  Preclinical Efficacy Failure of Human CNS-Derived Stem Cells for Use in the Pathway Study of Cervical Spinal Cord Injury.

Authors:  Aileen J Anderson; Katja M Piltti; Mitra J Hooshmand; Rebecca A Nishi; Brian J Cummings
Journal:  Stem Cell Reports       Date:  2017-02-14       Impact factor: 7.765

Review 4.  Treatment of Sarcoidosis: A Multidisciplinary Approach.

Authors:  Alicia K Gerke
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

Review 5.  Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns.

Authors:  Marc A Judson
Journal:  F1000Res       Date:  2019-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.